Meridian Bioscience Stock

Meridian Bioscience Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of Meridian Bioscience (VIVO) as of Aug 10, 2026 is 178.07. In the previous year, Cash Conversion Cycle (CCC) was 265.16 — a change of -32.85% (lower).

Cash Conversion Cycle

178.07

YoY

-32.85%

Last updated:

Cash Conversion Cycle (CCC) of Meridian Bioscience is 2026 178.07 . Cash Conversion Cycle (CCC) of Meridian Bioscience was 2025 265.16 . It decreases by -32.85% lower compared to the previous year.
Access this data via the Eulerpool API

Meridian Bioscience Stock analysis

What does Meridian Bioscience do? Meridian Bioscience Inc. is a global company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. The company was founded in 1976 by William J. Motto and initially focused on the development of enzyme immunoassays (EIA). Over the years, the company has grown and diversified its product offerings, becoming a leading provider of diagnostic test kits for acute and chronic medical conditions, infectious diseases, gastrointestinal infections, and virology. The company's success is attributed to its diverse range of test kits in various medical areas, including immunology, infectious diseases, sexually transmitted diseases, gastroenterology, and virology. Additionally, Meridian Bioscience Inc. stays up-to-date with the latest technological advancements in biotechnology to ensure the fast and effective performance of its tests. The company operates globally, collaborating with universities, research institutions, government agencies, and distributors to ensure the worldwide distribution and marketing of its products. In summary, Meridian Bioscience Inc. is an innovative company specializing in the development, manufacture, and distribution of test kits for the diagnosis of infectious diseases and other medical conditions. Its wide range of products, including immunology products, infectious disease diagnostics, sexually transmitted disease test kits, gastroenterology, virology, and molecular diagnostics, coupled with advanced technologies, provides fast, accurate, and reliable diagnostic support. Meridian Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Meridian Bioscience stock

Cash Conversion Cycle (CCC) of Meridian Bioscience is 178.07 in 2026.

Cash Conversion Cycle (CCC) of Meridian Bioscience changed from 265.16 to 178.07, representing a -32.85% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) Meridian Bioscience since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s Meridian Bioscience with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

Profitability — Meridian Bioscience

All Key Metrics — Meridian Bioscience